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Abstract 
Defining features of chronic airway diseases include abnormal and persistent 
inflammatory processes, impaired airway integrity and function, and increased 
susceptibility to recurrent respiratory infections. Phosphoinositide 3-kinases 
(PI3K) are lipid kinases, which contribute to multiple physiological and 
pathological processes within the airway, with abnormal PI3K signalling 
contributing to the pathogenesis of several respiratory diseases. Consequently, 
the potential benefit of targeting PI3K isoforms has received considerable 
attention, being viewed as a viable therapeutic option in inflammatory and 
infectious lung disorders.  The class I PI3K isoform, PI3Kį is of particular 
interest given its multiple roles in modulating innate and adaptive immune cell 
functions, airway inflammation and corticosteroid sensitivity. In this mini-review, 
we explore the role of PI3Kįin airway inflammation and infection, focusing on 
oxidative stress, ER stress, histone deacetylase 2 (HDAC2) and neutrophil 
function. We also describe the importance of PI3Kį LQ adaptive immune cell 
function, as highlighted by the recently described Activated PI3K Delta 
Syndrome (APDS), and draw attention to some of the potential clinical 
applications and benefits of targeting this molecule.  
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Abbreviations 
Chronic obstructive pulmonary disease (COPD) 
Bronchial epithelial cell (BEC) 
Cystic fibrosis transmembrane conductance regulator (CFTR) 
Alveolar macrophage (AM) 
Phosphoinositide 3-kinase (PI3K) 
Activated PI3K Delta Syndrome (APDS) 
Phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3) 
Phosphatidylinositol-3-phosphate (PI3P) 
Histone deacetylase 2 (HDAC2) 
Reactive oxidative species (ROS) 
Cigarette smoke (CS) 
Nuclear erythroid-2 related factor (Nrf2) 
Protein kinas B (AKT) 
Ovalbumin (OVA) 
Lipopolysaccharide (LPS) 
Interleukin-6/8/17 (IL-6/IL-8/IL-17) 
Vascular endothelial growth factor (VEGF) 
Airway hyper-responsiveness (AHR) 
Endoplasmic Reticulum (ER) 
Immunoglobulin E/M/A/G (IgE/IgM/IgA/IgG) 
Tumor necrosis factor D (TNFD) 
Neutrophil elastase (NE) 
Metalloproteinase-9 (MMP-9) 
Activation-induced cytidine deaminase (AID) 
Cytomegalovirus (CMV) 
Epstein-Barr virus (EBV) 
Monocyte-derived macrophages (MDMs) 
Bacillus Calmette Guerin (BCG) 
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Introduction  
Inspired oxygen is distributed throughout the lungs via the branching airways , 
diffusing across the alveolar membrane into the circulating red blood cells. 
Environmental toxins and pathogens also enter the lungs, potentially inciting 
inflammatory reactions and/or establishing intra-pulmonary infections. Airway 
diseases such as chronic obstructive pulmonary disease (COPD) and 
bronchiectasis are characterized by persistent and damaging airway 
inflammation, both compounded by and perpetuating respiratory infection. 
COPD is the most prevalent chronic respiratory disease globally, and is 
triggered by inhaled insults including smoke (from cigarettes and biomass fuels) 
and pollution. It is characterized by progressive, non-reversible airflow 
limitation, associated with persistent airway inflammation.  Bronchiectasis 
(which may co-exist with COPD) is associated with airway damage due to 
severe or recurrent infection (often in the context of impaired adaptive 
immunity) or aberrant inflammation, and is characterized by airway damage 
and dilatation with resulting impairment of lung defense.  
.  
Bronchial epithelial cells (BECs) sit at the interface between external and 
internal environments and are thus the initial target of inhaled insults, which 
initiate processes such as TLR signalling, oxidative stress and endoplasmic 
reticulum (ER) stress (NyunoyaYDQW¶:RXW). Consequences include enhanced 
secretion of chemokines and cytokines (Mio, Yanigasawa), 
initiating/perpetuating aberrant inflammatory cell accumulation (Hoenderdos 
Condliffe); airway cell apoptosis (Henson); and mucus hyper-secretion and 
CFTR dysfunction, which contribute to impaired ciliary function and small 
airway luminal obstruction (Gao). Ciliary dysfunction (Yasghi and Dolovich) and 
diminished anti-microbial peptide release from damaged epithelial cells is 
compounded by decreased alveolar macrophage (AM) phagocytic capacity (for 
both invading pathogens and apoptotic cells) (Donnelly and Barnes), together 
contributing to both the recurrent and damaging disease exacerbations that 
punctuate the disease course, and to microbiome disturbance (Sze, Wang). A 
vicious cycle is established, with infection further perpetuating airway 
inflammation. BEC-, AM- and pathogen-derived mediators all recruit 
neutrophils (Hoendereos Condliife), which secrete a wide range of mediators 
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(such as proteases, most classically neutrophil elastase (NE), and reactive 
oxygen species (ROS)) that contribute to COPD pathogenesis (Hoenderdos 
Condliffe). Finally, perturbed adaptive immunity (particularly B cell dysfunction) 
is associated development of bronchiectasis, and there is increasing evidence 
(eg abundant lymphoid follicles and T cell airway infiltration) that B and T cell 
dysfunction is also associated with COPD (reviewed in Caramori), although the 
significance of these findings is not yet fully established.  
 
Symptomatic treatments for airway disease such as bronchodilators have 
limited efficacy and little impact on disease progression. There is evidence that 
anti-inflammatory effects of oral glucocorticoids are of benefit in COPD 
exacerbations (Niewoehner, Woods), the use of longterm inhaled 
corticosteroids is currently recommended only for certain COPD endotypes 
such frequent exacerbators (Hurst, Magnussen) or those with eosinophilia 
(Bafadel). Antibiotics with anti-inflammatory function such as macrolides have 
been shown to be beneficial in both COPD (Taylor) and bronchiectasis (Hill), 
but longterm outcomes are unknown, and this strategy confers the risk of 
promoting anti-microbial resistance (Taylor, Hill). Therapies directed at 
neutrophil-derived products such as NE and myeloperoxidase have limited 
efficacy (Nordenmark, Stockley) except in highly specific circumstances such 
as individual with Į1-antitrypsin deficiency, who are more susceptible ton NE-
mediated damage and who may derive limited benefit from regular treatment 
with Į1-antitrypsin (Parr) There is thus an ongoing need for novel treatments 
which can modulate the multiple cellular targets contributing to airway disease. 
 
Airway defences may be further compromised by maladaptive innate and 
adaptive immune responses. The regulation of these events is complex, with 
various signalling pathway networks mediating downstream events initiated by 
ligation of cell surface receptors. The phosphoinositide 3-kinase (PI3K) 
pathway regulates responses across multiple cell types and mediates 
pleiotropic functions in both normal physiology and disease pathophysiology. 
PI3K signalling is important in regulating airway epithelial function, myeloid cell 
recruitment and activation, and B and T lymphocyte development and effector 
function. As such, aberrant PI3K signalling can thus contribute to a range of 
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respiratory diseases (Figure 1) depending on the inciting injury, target cell 
types, and the precise PI3K isoform affected. This mini-review will focus on the 
impact of disturbances of PI3KG function, in particular in the setting of COPD 
and a recently described immune deficiency, the Activated PI3K Delta 
Syndrome (APDS). 
 
Brief overview of Class I PI3Ks 
Class I PI3Ks, the most extensively studied group of lipid kinases, exist as 
heterodimeric complexes FRPSULVLQJSĮȕį RUȖFDWDO\WLFVXEXQLWs, with 
each isoform named according to the catalytic subunit present; their activity is 
controlled by several regulatory subunits (p85, p55 and p50 regulate SĮȕ 
and į, whilst p110Ȗ is separately regulated by p101 or p84). They share the 
ability to phosphorylate the 3rd hydroxyl group of membrane-localised 
phosphoinositides, generating a network of signalling secondary messengers. 
The best characterised, phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3) 
and phosphatidylinositol-3-phosphate (PI3P), facilitate the recruitment and 
activation of several downstream effector proteins, (e.g Protein Kinase B/Akt) 
that coordinate numerous signalling, and regulated intracellular vesicular 
trafficking processes, thereby controlling functions such as cell growth, 
migration and survival (reviewed in detail in (1)). The four Class I PI3K isoforms 
play distinct roles within the airway and elsewhere, and their tissue distribution 
varies accordingly. 3,.ĮDQG3,.ȕare widely distributed, whereas PI3KȖDQG
PI3Kį are predominantly but not exclusively expressed within leukocytes, 
playing important roles in both innate and adaptive immunity.  
 
PI3KG and airway inflammation 
Pharmacological studies plus genetic evidence, including the recently 
described APDS, have implicated dysfunctional PI3Kį signalling in airway 
inflammation, and studies exploring the potential therapeutic benefit of targeting 
PI3Kį have yielded encouraging results. For example, either aerosolised or 
systemically administered dual selective 3,.įȖ LQKLELWRUs reduced 
inflammatory cell infiltrates in murine models of inflammatory lung disease, 
including airway neutrophilia induced by inhaled cigarette smoke (CS) or 
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lipopolysaccharide (LPS) and ovalbumin (OVA)-induced asthma, 
demonstrating the potential effectiveness of both delivery routes in these 
settings (2, 3). Furthermore, selectively targeting PI3KG using the isoform 
specific inhibitor, IC87114, diminished allergen-induced airway inflammation 
and airway hyper-responsiveness (AHR) (4) ZLWK 3,.į NLQDVH-dead mice 
yielding similar results in comparable models (5, 6). More recently, a clinical 
study exploring the efficacy of a new inhaled PI3KG inhibitor (GSK2269557) 
within a COPD patient cohort demonstrated reduced sputum IL-8 and IL-6 
levels (7), further highlighting the anti-inflammatory potential of targeting this 
molecule in chronic lung disease.  Depending on the balance of the cell types 
and functional responses affected by aberrant PI3KG signalling, airway 
inflammation or respiratory infection (or both) may result (Figure 1). 
PI3KG, oxidative stress and histone deacetylase 2  
Enhanced oxidative stress is characteristic of chronic lung diseases, with 
reactive oxygen species (ROS) production influenced by external 
environmental factors such as CS, and by the interplay of genetic abnormalities 
(e.g. cystic fibrosis) with inflammatory insults (8). PI3Ks have been associated 
with ROS generation and oxidative stress at multiple levels (Figure 2A): 
augmenting ROS produced by normal cellular metabolism, infection and/or 
inflammatory cell activation, being activated in response to ROS, and regulating 
antioxidant expression under certain conditions via nuclear erythroid-2 related 
factor (Nrf2) (9). Importantly, activation of PI3KG has been shown to reduce the 
activity of histone deacetylase 2 (HDAC2) (Figure 2A), which modifies DNA-
binding proteins to suppress inflammatory gene expression in response to CS-
induced oxidative stress, hence perpetuating inflammatory processes in this 
setting (10). COPD patients with neutrophilic airway inflammation typically 
respond poorly to steroid therapy (11), a phenomenon attributed in part to a 
reduction in HDAC2 expression and activity (12). Importantly, restoration of 
HDAC2 activity and consequently corticosteroid sensitivity, has been 
demonstrated both in in vitro and in vivo models of COPD following direct 
targeting of PI3KG (10, 12, 13). HDAC2 activity in alveolar macrophages was 
found to be reduced in moderate to severe asthmatics (14), in whom steroid 
resistance is also a frequent challenge (15), particularly when there is persistent 
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lymphocyte activation or a prominent neutrophilic component (16). PI3KG is 
highly expressed within these cell types, and recent work demonstrates that T-
cell derived cytokine generation can be suppressed by PI3KG inhibition, with 
multiple T cell lineages targeted (17). Similar observations have also been 
demonstrated specifically in the context of COPD and asthma, with PI3KG 
inhibition broadly reducing lymphocyte-derived cytokines such as IL-17 (Figure 
2A) (18, 19). IL-17 is elevated within the airways of COPD patients and severe 
asthmatics, coordinating neutrophilic inflammation in these diseases (20, 21). 
Given that IL-17 has been shown to reduce HDAC activity and glucocorticoid 
sensitivity in bronchial epithelial cell lines (22), that similar effects observed in 
macrophages are associated with oxidative stress and PI3KG activity (23), and 
that corticosteroids have little anti-inflammatory effect on COPD lung 
neutrophils (24), it is plausible that targeting PI3KG would not only alleviate 
detrimental inflammation observed within lung disease, but also 
improve/restore glucocorticoid sensitivity.  
 
PI3KG and Endoplasmic Reticulum (ER) stress  
$OWKRXJK SULPDULO\ H[SUHVVHG LQ OHXNRF\WHV 3,.į FDQ EH detected in non-
immune cells albeit at much lower levels (25, 26). Furthermore, 3,.į
expression is inducible under certain inflammatory conditions, for example in 
TNFD-stimulated endothelial cells (25). Increased PI3KG expression was 
observed in asthmatic versus healthy volunteer airway epithelial sample in 
human bronchial biopsies, although the expression was predominantly nuclear 
rather than cytoplasmic (18); the significance of this nuclear localisation is 
unclear.  Might airway epithelial 3,.į SOD\ a role in regulating airway 
inflammation in response to infection? This hypothesis is supported by recent 
studies GHPRQVWUDWLQJWKDW/36H[SRVXUHSURPRWHV3,.įDFWLYDWLRQ(27), and 
that 3,.į-dependent regulation of aspergillus-induced airway inflammation 
occurs via the induction of ER stress pathways (Figure 2A) (28). Several studies 
highlight the importance of ER stress in driving inflammation in both asthma 
and COPD, particularly in the context of oxidative stress (28-30), with prolonged 
activation contributing to airway remodelling (31). Whilst the interplay between 
airway inflammation, ER stress and 3,.į remains poorly understood, ER 
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VWUHVVDQG3,.įDFWLYLW\DUHERWKDVVRFLDWHGZLWKVWHURLG-resistance within lung 
disease via oxidative stress-dependent processes (23, 30), hence targeting 
3,.į PD\ UHJXODWH DGYHUVH LQIODPPDWRU\ SURFHVVHV WKURXJK PXOWLSOH
mechanisms.  
 
PI3KG and aberrant neutrophil function in COPD 
Neutrophils are of key importance in pathogen clearance but are also a 
prominent feature of airway inflammation in chronic lung diseases, where they 
are thought to exert detrimental effects (32). PI3K signalling influences several 
key neutrophil functions including chemotaxis, oxidative burst and survival (33-
35). Neutrophils from COPD patients (36) and elderly individuals (37) exhibit 
less accurate chemotaxis, a defect that is reversed by PI3KįRU3,.J inhibition 
(36). Although the precise function of 3,.įin this context has not been fully 
elucidated, its role is likely to be significant given its known role in regulating 
neutrophil trafficking and directional movement (35, 38). Neutrophil activation 
and degranulation also play important roles in the pathogenesis of chronic 
airway diseases, with dysregulated ROS, neutrophil elastase (NE) and matrix 
metalloproteinase-9 (MMP-9) contributing to lung tissue damage (Figure 2A) 
and disease severity in COPD (39). In vitro studies reveal that NE and MMP-9 
release is PI3K-dependent (40), and although not solely attributed to 3,.įLW
is OLNHO\ WR LQYROYH 3,.į LQ FHUWDLQ FRQWH[WV JLYHQ WKDW 71)D-induced NE 
release can be reduced E\3,.įLQKLELWLRQ(41). Furthermore, specific targeting 
of PI3KG suppressed ROS release from neutrophils obtained from both stable 
and exacerbating COPD patients (42), providing further evidence to support the 
targeting of PI3KG to manage unfavourable neutrophilic activity in this disease. 
The outcomes of clinical trials of PI3KG inhibition in COPD (and other airway 
diseases) are eagerly awaited. 
 
Lessons from the Activated PI3KG Syndrome (APDS) 
The recently described Activated PI3KDelta Syndrome (APDS) provides further 
evidence that aberrant PI3Kį activity can drive lung disease, in particular 
recurrent respiratory infections and airway damage (43). The initial reports 
described mutations (E1021K, E525K, N334K)  in the p110į catalytic subunit 
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of PI3Kį (43, 44); further p110į mutations have been identified, as have splice 
site mutations which lead to loss of exon 11 of the p85 regulatory subunit (45, 
46). All of the mutations described to date affect the interaction of the catalytic 
and regulatory subunits (47), and all are gain-of-function leading to enhanced 
PI3Kį signaling (for example there is both enhanced constitutive and 
stimulated activation of the AKT/PKB and mTOR pathways), Whilst there are 
some differences in the clinical manifestatLRQVLQ$3'6SįPXWDWLRQVDQG
APDS2 (p85 mutations), respiratory infections are near universal in both 
settings, and there is an extremely high incidence of bronchiectasis (48, 49). 
Augmented PI3Kį DFWLYLW\ KDV EHHQ FRQILUPHG both in vitro and in patient-
derived B and T lymphocytes (43, 44), with clinical and laboratory evidence 
VXJJHVWLQJDEHUUDQW3,.įVLJQDlling in myeloid cells also (43, 50). 
 
B Lymphocytes in APDS 
Whilst PI3KįKDVEHHQVKRZQWR have a subtle influence on B cell development 
in mouse models (51), APDS patients have greatly increased circulating 
transitional (immature) B cells (43, 44), an unexpected observation that is 
currently unexplained but which may serve as a biomarker for aberrant PI3Kį 
activation. Enhanced PI3K signalling in mature B cells impairs antibody class 
switching (from IgM to IgA/IgG) (52), and this may be due at least in part to the 
role of PI3Kį LQ UHJXODWLQJ WKH H[SUHVVLRQ DQG IXQFWLRQ RI AID (activation-
induced cytidine deaminase) (53). The majority (although not all) APDS 
patients have increased levels of circulating IgM and many also have low 
circulating IgG/IgA levels (48, 49), consistent with a defect in class switch 
recombination (Figure 2B); in limited studies, defective class switching in 
APDS-derived cells was improved by PI3KįLQKLELWLRQ(44), supporting a causal 
link. The clinical manifestations of APDS are dominated by respiratory 
infections that are closely associated with antibody deficiency (principally 
encapsulated bacteria Streptococcus pneumoniae and Haemophilus 
influenzae). These recurrent infections (including otitis media, bronchitis and 
pneumonia) lead to a high incidence of end-organ damage including hearing 
loss and bronchiectasis, further impairing host defence and increases infection 
susceptibility. However, the near-universal respiratory infections and high 
incidence of bronchiectasis in APDS do not correlate precisely with antibody 
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deficiency (for example, higher frequency of reduced IgG but lower incidence 
of bronchiectasis in APDS2 (49) versus APDS1 (48)), suggesting that antibody-
independent B cell properties or other host defence cellular dysfunction may 
play a role (see below); alternatively or additionally, perturbed airway cell 
function with enhanced oxidative and ER stress as described above may 
contribute to diminished lung defences. 
 
T Lymphocytes in APDS 
Patients with APDS also experience an excess of respiratory infections with 
viruses such as Adenovirus, Echovirus, Coxsaskievirus and Respiratory 
Syncytial Virus (48), and also have a marked propensity to develop systemic 
herpes viral infections (with CMV and EBV in particular: (43, 44)), marking 
APDS as a combined rather than just a B cell immunodeficiency disorder. 
APDS is associated with pronounced circulating T cell abnormalities, including 
hyper-proliferation, differentiation to terminal effector cells associated with 
dysregulated cytokine production, T cell senescence (44) and increased 
sensitivity to activation-induced apoptosis (43, 54) (Figure 2B). Excessive viral 
infections may also reflect that fact that many viral pathogens subvert host cell 
PI3K signalling to support replication (55), hence constitutively enhanced PI3K 
activation may tip the balance in favour of the pathogen. Whether enhanced 
PI3Kį signalling in airway epithelial cells promotes viral entry and/or replication 
in APDS is currently unknown, but it is interesting to note that increased airway 
cell PI3KĮ expression is COPD results in increased susceptibility to influenza 
viral infection (56). 
 
Myeloid cells in APDS 
Myeloid dysfunction has been little studied in APDS, with initial (but limited) 
studies in neutrophils in response to soluble agonists suggesting at least partial 
preservation of function (43). However, with reference to the data of Sapey et 
al. (36) implicating PI3Kį in the impaired chemotactic ability of COPD 
neutrophils, the directional migration of APDS neutrophils has not been 
explored, and the incidence of COPD in APDS is unknown (it is a rare disease 
with many patients dying young). However, monocytes-derived macrophages 
(MDMs) from a single APDS patient demonstrated impaired ability to kill 
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Bacillus Calmette Guèrin (BCG) in vitro, with macrophage mycobactericidal 
activity restored by the isoform-selective PI3Kį inhibitor IC87114 (50). Of 
interest, instances of significant local infection following BCG vaccination have 
been reported following BCG vaccination in APDS patients (48) (Figure 2B). 
Impaired alveolar macrophage function in APDS could contribute to defects in 
handling respiratory bacterial pathogens, as has been demonstrated in COPD 
(57), although inhibition of PI3KįGLGQRW UHVWRUHSKDJRF\WLFDELOLW\RI&23'
macrophages (58). Further studies of myeloid cell signalling and function in 
APDS would be of considerable interest. 
 
Concluding remarks 
PI3K signalling has a fundamental role in various airway responses, 
coordinating immune cell effector functions and airway epithelial stress 
responses. Considerable progress has been made in deciphering the multiple 
roles of 3,.į within lung disease [Figure 1], with much insight gained from the 
recently described APDS. Dysregulated PI3Kį activity contributes to lung 
disease pathology through numerous mechanisms: potentiating inflammation, 
modulating epithelial and inflammatory cell function, and increasing 
susceptibility to viral and bacterial respiratory infections. 3,.į VSHFLILF
inhibitors are already in development for the treatment of COPD (19) and APDS 
(59), with the prospect to inhibit both systemic targets (Rao: eg to limit 
neutrophil recruitment) and (with inhaled therapy, Cahn) to deliver maximal 
inhibition to the airway epithelial cells and recruited inflammatory cells. 
)XUWKHUPRUH FRPELQLQJ3,.į LQKLELWRUVZLWKH[LVWLQJ (eg macrolides, which 
also target a range of inflammatory signals, and corticosteroids, thereby 
inhibiting both corticosteroid-sensitive and corticosteroid-resistant pro-
inflammatory pathways) and novel therapies HJFRPELQHG3L.ȖįLQKLELWRUV
to maximize the inhibitory effect on both innate and adaptive immunity) may 
enhance treatment effectiveness, particularly in the context of corticosteroid 
resistance, and may provide opportunities to tailor therapies for individual 
patient needs. 
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Figure 1. Abnormal PI3K signalling within the lung. Aberrant PI3Kį 
signalling can contribute to a range of respiratory diseases, depending on the 
inciting stimulus and the cell types affected. Dysfunction of the same targets es 
(including airway epithelial cells, myeloid cells, and B and T lymphocytes) may 
contribute to infection or inflammation, or both may occur simultaneously, 
determining the disease phenotype.  
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)LJXUH7KHPXOWLSOHUROHVRI3,.įin COPD and APDS  
A. COPD. 3,.į activity is elevated within the COPD airway, being further 
enhanced by oxidative stress arising through exposure to cigarette smoke and 
respiratory pathogen infection (I). Enhanced 3,.įDFWLYLW\ within the airway 
epithelium, macrophages and T cells reduces HDAC2 activity (II), impairing 
corticosteroid effectiveness, enhancing proinflammatory cytokine generation 
DQG LQIODPPDWRU\ FHOO UHFUXLWPHQW (QKDQFHG 3,.į DFWLYLW\ DQG R[LGDWLYH 
stress within the epithelium results in the activation of ER stress processes (III), 
an important pathological driver of COPD. B. APDS. (SLWKHOLDO3,.įDFWLYLW\ (I) 
and T cell dysfunction/senescence (II) promote viral entry, replication and 
epithelial damage.  Failure of antibody class-switching (III) and impaired 
myeloid function (IV), compounded by viral-induced damage, leads to 
increased bacterial infection (V) and further airway damage, with pro-
inflammatory cytokines produced by multiple cell types propagating 
dysregulated inflammation. 
 
 
 
